POXEL SA (POXEL.PA)
FR0012432516 - Common Stock
Overall POXEL gets a fundamental rating of 1 out of 10. We evaluated POXEL against 75 industry peers in the Biotechnology industry. POXEL has a bad profitability rating. Also its financial health evaluation is rather negative. POXEL is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
POXEL had negative earnings in the past year.
In the past year POXEL has reported a negative cash flow from operations.
POXEL had negative earnings in each of the past 5 years.
POXEL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
POXEL has a Return On Assets of -727.56%. This is amonst the worse of the industry: POXEL underperforms 97.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -727.56% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-287.1%
ROA(5y)-189.16%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of POXEL (0.05%) is comparable to the rest of the industry.
POXEL's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for POXEL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 0.05% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-92.04%
GM growth 5YN/A
2. Health
2.1 Basic Checks
POXEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for POXEL has been increased compared to 1 year ago.
Compared to 5 years ago, POXEL has more shares outstanding
POXEL has a worse debt/assets ratio than last year.
2.2 Solvency
POXEL has an Altman-Z score of -33.72. This is a bad value and indicates that POXEL is not financially healthy and even has some risk of bankruptcy.
POXEL has a worse Altman-Z score (-33.72) than 88.57% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -33.72 |
ROIC/WACCN/A
WACC6.22%
2.3 Liquidity
A Current Ratio of 0.34 indicates that POXEL may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.34, POXEL is doing worse than 94.29% of the companies in the same industry.
POXEL has a Quick Ratio of 0.34. This is a bad value and indicates that POXEL is not financially healthy enough and could expect problems in meeting its short term obligations.
POXEL has a Quick ratio of 0.34. This is amonst the worse of the industry: POXEL underperforms 94.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.34 | ||
| Quick Ratio | 0.34 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 0.16% over the past year.
POXEL shows a strong growth in Revenue. In the last year, the Revenue has grown by 193.92%.
Measured over the past years, POXEL shows a very negative growth in Revenue. The Revenue has been decreasing by -49.84% on average per year.
EPS 1Y (TTM)0.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.34%
Revenue 1Y (TTM)193.92%
Revenue growth 3Y-33.73%
Revenue growth 5Y-49.84%
Sales Q2Q%73.6%
3.2 Future
POXEL is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -32.66% yearly.
Based on estimates for the next years, POXEL will show a very strong growth in Revenue. The Revenue will grow by 187.77% on average per year.
EPS Next Y-58.3%
EPS Next 2Y-32.24%
EPS Next 3Y-32.66%
EPS Next 5YN/A
Revenue Next Year3450%
Revenue Next 2Y169.26%
Revenue Next 3Y187.77%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for POXEL. In the last year negative earnings were reported.
Also next year POXEL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
POXEL's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. POXEL is cheaper than 87.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 9.04 |
4.3 Compensation for Growth
A cheap valuation may be justified as POXEL's earnings are expected to decrease with -32.66% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-32.24%
EPS Next 3Y-32.66%
5. Dividend
5.1 Amount
No dividends for POXEL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
POXEL SA
EPA:POXEL (12/20/2024, 7:00:00 PM)
0.1276
0 (-1.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners7.99%
Inst Owner ChangeN/A
Ins Owners3.17%
Ins Owner ChangeN/A
Market Cap6.85M
Analysts84.44
Price Target3.57 (2697.81%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.46 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.04 |
EPS(TTM)-1.08
EYN/A
EPS(NY)-1.18
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0.04
BVpS-0.91
TBVpS-0.91
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -727.56% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 0.05% | ||
| FCFM | N/A |
ROA(3y)-287.1%
ROA(5y)-189.16%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-92.04%
GM growth 5YN/A
F-Score2
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 9.45 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.34 | ||
| Quick Ratio | 0.34 | ||
| Altman-Z | -33.72 |
F-Score2
WACC6.22%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.34%
EPS Next Y-58.3%
EPS Next 2Y-32.24%
EPS Next 3Y-32.66%
EPS Next 5YN/A
Revenue 1Y (TTM)193.92%
Revenue growth 3Y-33.73%
Revenue growth 5Y-49.84%
Sales Q2Q%73.6%
Revenue Next Year3450%
Revenue Next 2Y169.26%
Revenue Next 3Y187.77%
Revenue Next 5YN/A
EBIT growth 1Y44.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year204.08%
EBIT Next 3Y-1.71%
EBIT Next 5YN/A
FCF growth 1Y35.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.92%
OCF growth 3YN/A
OCF growth 5YN/A